Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of "Hold" by Analysts

Key Points

• Illumina, Inc. has an average analyst rating of "Hold" from 19 research firms, with 2 sell, 11 hold, and 6 buy recommendations.
• The company's recent quarterly earnings report showed an EPS of $1.19, exceeding expectations but with a 4.8% decline in revenue year-over-year.
• Illumina's market cap is approximately $14.09 billion, with a current stock price of $91.69 and a 52-week range between $68.70 and $156.66.

Shares of Illumina, Inc. (NASDAQ:ILMN - Get Free Report) have been given an average rating of "Hold" by the nineteen research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eleven have issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $123.0556.

ILMN has been the topic of a number of research reports. Royal Bank Of Canada set a $124.00 price objective on Illumina in a report on Tuesday, September 2nd. Daiwa America lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Wall Street Zen cut shares of Illumina from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Robert W. Baird increased their price objective on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research report on Monday, July 28th. Finally, Daiwa Capital Markets downgraded shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 target price on the stock. in a research note on Tuesday, August 12th.

Illumina Stock Performance

NASDAQ:ILMN opened at $91.69 on Friday. The company has a market cap of $14.09 billion, a P/E ratio of 11.61, a P/E/G ratio of 2.22 and a beta of 1.43. The firm's 50 day moving average is $99.62 and its two-hundred day moving average is $89.39. Illumina has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analysts' expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business's quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Analysts expect that Illumina will post 4.51 EPS for the current year.

Institutional Investors Weigh In On Illumina

Several institutional investors and hedge funds have recently modified their holdings of ILMN. Rise Advisors LLC raised its holdings in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock valued at $28,000 after buying an additional 224 shares during the period. Parkside Financial Bank & Trust raised its stake in shares of Illumina by 65.7% during the second quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company's stock valued at $28,000 after purchasing an additional 115 shares during the period. Rakuten Securities Inc. raised its stake in shares of Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock valued at $29,000 after purchasing an additional 270 shares during the period. Center for Financial Planning Inc. acquired a new position in shares of Illumina during the first quarter worth $33,000. Finally, PFS Partners LLC boosted its stake in shares of Illumina by 400.0% in the first quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock valued at $40,000 after purchasing an additional 400 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.